Trial Profile
Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy (JBCRG-11CPA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Cyclophosphamide
- Indications Breast cancer
- Focus Therapeutic Use
- 28 Mar 2019 Status changed from active, no longer recruiting to completed.
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 23 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.